Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01814410 · ClinicalTrials.gov registry record · Early Phase 1

Interactive Effects of IV Ethanol and IV Nicotine

A Early Phase 1 study, sponsored by Yale University.

Completed
Registry status
Early Phase 1
Development phase
5
Enrollment target

NCT01814410 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01814410, a Early Phase 1 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Early Phase 1
Development phase
5 participants
Enrollment target

Study Summary

There are mixed reports on nicotine's effects on ethanol-induced impairment in cognitive performance and behavior in humans. The main objective of this study is to characterize the interactive effects of acute intravenous (IV) ethanol and nicotine administration on cognition and behavior in healthy smokers. The general hypothesis is that nicotine will attenuate the negative effects of ethanol on cognition and subjective stimulant/sedative effects of ethanol.

Interventions

  • DRUG Intravenous ethanol placebo plus nicotine infusions
  • DRUG intravenous ethanol 40mg% plus nicotine infusions
  • DRUG intravenous ethanol 100mg% plus nicotine infusions

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2013-02-22
Est. Completion 2014-06
Phase Early Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT01814410

The ClinicalTrials.gov registry entry for NCT01814410 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Intravenous ethanol placebo plus nicotine infusions is the first listed.

NCT01814410 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01814410 about?

NCT01814410 is a clinical study titled "Interactive Effects of IV Ethanol and IV Nicotine". There are mixed reports on nicotine's effects on ethanol-induced impairment in cognitive performance and behavior in humans. The main objective of this study is to characterize the interactive effects of acute intravenous (IV) ethanol and nicotine administration on cognition and behavior in healthy ...

What is the current status of trial NCT01814410?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2013-02-22. Estimated completion is 2014-06.

What interventions are being tested in trial NCT01814410?

The interventions under investigation include: Intravenous ethanol placebo plus nicotine infusions (DRUG), intravenous ethanol 40mg% plus nicotine infusions (DRUG), intravenous ethanol 100mg% plus nicotine infusions (DRUG).

Who is sponsoring clinical trial NCT01814410?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.